MedPath

PHARMASOFT

🇲🇦Morocco
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:7

Trial Phases

3 Phases

Phase 2:1
Phase 3:4
Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (57.1%)
Phase 4
2 (28.6%)
Phase 2
1 (14.3%)

Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

Phase 2
Completed
Conditions
Primary Open-Angle Glaucoma (POAG)
Interventions
Other: Placebo
First Posted Date
2025-03-30
Last Posted Date
2025-03-30
Lead Sponsor
Pharmasoft
Target Recruit Count
102
Registration Number
NCT06903156
Locations
🇷🇺

Kirov Regional State Budgetary Healthcare Institution "Kirov Clinical Ophthalmological Hospital", Kirov, Russian Federation

🇷🇺

Federal State Budgetary Educational Institution of Higher Education "Moscow State Medical and Dental Institute named after A.I. Evdokimov" of the Ministry of Health of the RF, Moscow, Russian Federation

🇷🇺

Federal State Autonomous Institution "Intersectoral Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Health of the RF, Moscow, Russian Federation

and more 4 locations

Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12

Phase 3
Completed
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Anxiety Disorders and Symptoms
Interventions
Drug: Mexidol + Placebo
Drug: Placebo
First Posted Date
2025-03-03
Last Posted Date
2025-03-03
Lead Sponsor
Pharmasoft
Target Recruit Count
333
Registration Number
NCT06854601
Locations
🇷🇺

State Autonomous Healthcare Institution of the Sverdlovsk Region "Multispecialty Clinical Medical Center 'Bonum', Yekaterinburg, Ural region, Russian Federation

🇷🇺

Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" Ministry of Health of the Russian Federation, Kazan, Russian Federation

🇷🇺

State Budgetary Healthcare Institution "Specialized Clinical Psychiatric Hospital №1" of the Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation

and more 11 locations

Safety and Efficacy of Sequential Treatment with Mexidol® in Patients with Chronic Cerebral Ischemia

Phase 3
Completed
Conditions
Chronic Cerebral Ischemia
Interventions
Drug: Placebo
First Posted Date
2025-02-19
Last Posted Date
2025-02-25
Lead Sponsor
Pharmasoft
Target Recruit Count
318
Registration Number
NCT06834490
Locations
🇷🇺

Municipal Autonomous Healthcare Insitution of the Order of the Red Banner of Labour "City Clinical Hospital No.1", Chelyabinsk, Russian Federation

🇷🇺

State Budget Healthcare Institution of the Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital No.1", Ekaterinburg, Russian Federation

🇷🇺

Regional Budget Healthcare Institution "Ivanovo Regional Clinical Hospital", Ivanovo, Russian Federation

and more 11 locations

The Study of Efficacy and Safety of Mexidol® in Stroke Therapy (MIR)

Phase 3
Completed
Conditions
Ischemic Stroke
Interventions
Drug: Placebo
First Posted Date
2024-05-31
Last Posted Date
2024-07-17
Lead Sponsor
Pharmasoft
Target Recruit Count
304
Registration Number
NCT06437626
Locations
🇰🇿

Almaty City Hospital № 7, Almaty, Kazakhstan

🇷🇺

Tatarstan Republican Clinical Hospital, Kazan, Russian Federation

🇷🇺

Interregional Clinical Diagnostic Center, Kazan, Russian Federation

and more 16 locations

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Phase 4
Completed
Conditions
Primary Open-Angle Glaucoma (POAG)
Interventions
First Posted Date
2024-05-31
Last Posted Date
2024-05-31
Lead Sponsor
Pharmasoft
Target Recruit Count
80
Registration Number
NCT06437639
Locations
🇷🇺

Tyumen Scientific Center of the Russian Academy of Sciences, Tyumen, Russian Federation

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath